| Not Yet Recruiting | Shared Decision Making for Antipsychotic Medications NCT05416658 | New York State Psychiatric Institute | N/A |
| Not Yet Recruiting | REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health) NCT07006935 | Case Western Reserve University | N/A |
| Completed | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder NCT07116694 | BioXcel Therapeutics Inc | Phase 2 |
| Not Yet Recruiting | Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schi NCT03974620 | Pakistan Institute of Living and Learning | N/A |
| Active Not Recruiting | Young Adults With Violent Behavior During Early Psychosis (Aim 2) NCT05756855 | Columbia University | N/A |
| Active Not Recruiting | Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography NCT06278246 | Centre for Addiction and Mental Health | — |
| Active Not Recruiting | REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group Intervention NCT06251908 | Amager Hospital | N/A |
| Terminated | Horyzons: Implementation and Integration in Clinical Practice NCT06002958 | University of North Carolina, Chapel Hill | N/A |
| Completed | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Di NCT06041646 | BioXcel Therapeutics Inc | Phase 4 |
| Withdrawn | Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in t NCT05974527 | Brigham and Women's Hospital | Phase 4 |
| Active Not Recruiting | EPI-MINN: Targeting Cognition and Motivation - National NCT05877716 | University of Minnesota | N/A |
| Recruiting | iTBS to Enhance Social Cognition in People With Psychosis NCT06118268 | Northwell Health | N/A |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III NCT05658510 | BioXcel Therapeutics Inc | Phase 3 |
| Recruiting | Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders NCT06423651 | Universitat Autonoma de Barcelona | N/A |
| Completed | Remote State Representation in Early Psychosis NCT05538832 | University of Minnesota | EARLY_Phase 1 |
| Completed | Academic-Community EPINET (AC-EPINET) NCT04497857 | Indiana University | N/A |
| Completed | Peripheral Immune System in Individuals With Schizophrenia NCT05109065 | Stanford University | — |
| Completed | Horyzons: Implementation in Clinical Practice NCT04673851 | University of North Carolina, Chapel Hill | N/A |
| Completed | Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders NCT04418011 | Centre for Addiction and Mental Health | N/A |
| Completed | ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention NCT04298450 | Centre for Addiction and Mental Health | N/A |
| Completed | Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis NCT05784948 | Chonbuk National University Hospital | N/A |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia NCT04268303 | BioXcel Therapeutics Inc | Phase 3 |
| Completed | Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis NCT04004416 | University of Michigan | Phase 4 |
| Completed | Early Psychosis Intervention - Spreading Evidence-based Treatment NCT03919760 | Centre for Addiction and Mental Health | N/A |
| Completed | Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial NCT04173572 | University of North Carolina, Chapel Hill | N/A |
| Unknown | Estradiol as add-on to Antipsychotics NCT04093518 | Tangent Data | Phase 3 |
| Unknown | Bazedoxifene -Treatment for Women With Schizophrenia NCT04113993 | The Alfred | Phase 4 |
| Completed | Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. NCT03510741 | Pakistan Institute of Living and Learning | Phase 2 |
| Unknown | Mindfulness Psychoeducation Program for Schizophrenia NCT03632278 | The Hong Kong Polytechnic University | N/A |
| Completed | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed Wi NCT03187769 | Alkermes, Inc. | Phase 3 |
| Completed | Minnesota Community-Based Cognitive Training in Early Psychosis NCT03079024 | University of Minnesota | N/A |
| Completed | Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy NCT03067311 | University of North Carolina, Chapel Hill | N/A |
| Completed | Research Into Antipsychotic Discontinuation and Reduction Trial NCT03559426 | University College, London | Phase 4 |
| Completed | Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophrenifor NCT03848234 | Tangent Data | Phase 3 |
| Completed | Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia NCT01082588 | Massachusetts General Hospital | Phase 4 |
| Completed | Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia NCT00595504 | Massachusetts General Hospital | Phase 4 |
| Completed | Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia NCT00407277 | Centre for Addiction and Mental Health | N/A |
| Completed | A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaff NCT00796081 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Completed | A Comparative Study of New Medications for Psychosis in Adolescents NCT00222495 | University of Minnesota | N/A |
| Completed | Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment NCT00161057 | UMC Utrecht | — |
| Terminated | Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients NCT00515489 | Janssen-Cilag, S.A. | — |
| Completed | Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants NCT00419146 | University Hospital, Aker | Phase 2 / Phase 3 |
| Unknown | Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis NCT00157313 | Bispebjerg Hospital | N/A |